BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 36737754)

  • 1. Widespread amyloidogenicity potential of multiple myeloma patient-derived immunoglobulin light chains.
    Sternke-Hoffmann R; Pauly T; Norrild RK; Hansen J; Tucholski F; Høie MH; Marcatili P; Dupré M; Duchateau M; Rey M; Malosse C; Metzger S; Boquoi A; Platten F; Egelhaaf SU; Chamot-Rooke J; Fenk R; Nagel-Steger L; Haas R; Buell AK
    BMC Biol; 2023 Feb; 21(1):21. PubMed ID: 36737754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.
    Poshusta TL; Sikkink LA; Leung N; Clark RJ; Dispenzieri A; Ramirez-Alvarado M
    PLoS One; 2009; 4(4):e5169. PubMed ID: 19365555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation.
    Mazzini G; Ricagno S; Caminito S; Rognoni P; Milani P; Nuvolone M; Basset M; Foli A; Russo R; Merlini G; Palladini G; Lavatelli F
    FEBS J; 2022 Jan; 289(2):494-506. PubMed ID: 34482629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate.
    Andrich K; Hegenbart U; Kimmich C; Kedia N; Bergen HR; Schönland S; Wanker E; Bieschke J
    J Biol Chem; 2017 Feb; 292(6):2328-2344. PubMed ID: 28031465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains.
    Morgan GJ; Kelly JW
    J Mol Biol; 2016 Oct; 428(21):4280-4297. PubMed ID: 27569045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Truncation of the constant domain drives amyloid formation by immunoglobulin light chains.
    Lavatelli F; Natalello A; Marchese L; Ami D; Corazza A; Raimondi S; Mimmi MC; Malinverni S; Mangione PP; Palmer MT; Lampis A; Concardi M; Verona G; Canetti D; Arbustini E; Bellotti V; Giorgetti S
    J Biol Chem; 2024 Apr; 300(4):107174. PubMed ID: 38499153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoglobulin light chain amyloid aggregation.
    Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M
    Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity.
    Oberti L; Rognoni P; Barbiroli A; Lavatelli F; Russo R; Maritan M; Palladini G; Bolognesi M; Merlini G; Ricagno S
    Sci Rep; 2017 Dec; 7(1):16809. PubMed ID: 29196671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis.
    Brumshtein B; Esswein SR; Sawaya MR; Rosenberg G; Ly AT; Landau M; Eisenberg DS
    J Biol Chem; 2018 Dec; 293(51):19659-19671. PubMed ID: 30355736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis.
    Lavatelli F; Mazzini G; Ricagno S; Iavarone F; Rognoni P; Milani P; Nuvolone M; Swuec P; Caminito S; Tasaki M; Chaves-Sanjuan A; Urbani A; Merlini G; Palladini G
    J Biol Chem; 2020 Dec; 295(49):16572-16584. PubMed ID: 32952127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro aggregation behavior of a non-amyloidogenic λ light chain dimer deriving from U266 multiple myeloma cells.
    Arosio P; Owczarz M; Müller-Späth T; Rognoni P; Beeg M; Wu H; Salmona M; Morbidelli M
    PLoS One; 2012; 7(3):e33372. PubMed ID: 22432016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations can cause light chains to be too stable or too unstable to form amyloid fibrils.
    Marin-Argany M; Güell-Bosch J; Blancas-Mejía LM; Villegas S; Ramirez-Alvarado M
    Protein Sci; 2015 Nov; 24(11):1829-40. PubMed ID: 26300552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased amyloidogenicity caused by mutational modulation of surface properties of the immunoglobulin light chain BRE variable domain.
    Kobayashi Y; Tsutsumi H; Abe T; Ikeda K; Tashiro Y; Unzai S; Kamikubo H; Kataoka M; Hiroaki H; Hamada D
    Biochemistry; 2014 Aug; 53(31):5162-73. PubMed ID: 25062800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.
    Kazman P; Vielberg MT; Pulido Cendales MD; Hunziger L; Weber B; Hegenbart U; Zacharias M; Köhler R; Schönland S; Groll M; Buchner J
    Elife; 2020 Mar; 9():. PubMed ID: 32151314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Free immunoglobulin light chains as a risk factor in renal and extrarenal complications.
    Cohen G; Hörl WH
    Semin Dial; 2009; 22(4):369-72. PubMed ID: 19708983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of IGLV2-14 light chain sequences of patients with AL amyloidosis or multiple myeloma.
    Berghaus N; Schreiner S; Poos AM; Raab MS; Goldschmidt H; Mai EK; Salwender HJ; Bernhard H; Thurner L; Müller-Tidow C; Weinhold N; Hegenbart U; Schönland SO; Huhn S
    FEBS J; 2023 Sep; 290(17):4256-4267. PubMed ID: 37097223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CDR1 and Other Regions of Immunoglobulin Light Chains are Hot Spots for Amyloid Aggregation.
    Ruiz-Zamora RA; Guillaumé S; Al-Hilaly YK; Al-Garawi Z; Rodríguez-Alvarez FJ; Zavala-Padilla G; Pérez-Carreón JI; Rodríguez-Ambriz SL; Herrera GA; Becerril-Luján B; Ochoa-Leyva A; Melendez-Zajgla J; Serpell L; Del Pozo-Yauner L
    Sci Rep; 2019 Feb; 9(1):3123. PubMed ID: 30816248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis of light chain amyloidogenicity: comparison of the thermodynamic properties, fibrillogenic potential and tertiary structural features of four Vlambda6 proteins.
    Wall JS; Gupta V; Wilkerson M; Schell M; Loris R; Adams P; Solomon A; Stevens F; Dealwis C
    J Mol Recognit; 2004; 17(4):323-31. PubMed ID: 15227639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenic potential of human monoclonal immunoglobulin light chains: relationship of in vitro aggregation to in vivo organ deposition.
    Myatt EA; Westholm FA; Weiss DT; Solomon A; Schiffer M; Stevens FJ
    Proc Natl Acad Sci U S A; 1994 Apr; 91(8):3034-8. PubMed ID: 8159701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural analysis of the amyloidogenic kappa Bence Jones protein (FUR).
    Odani S; Komori Y; Gejyo F
    Amyloid; 1999 Jun; 6(2):77-88. PubMed ID: 10439113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.